Analysts expect Alimera Sciences Inc (NASDAQ:ALIM) to announce sales of $13.24 million for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Alimera Sciences’ earnings. The lowest sales estimate is $13.20 million and the highest is $13.28 million. Alimera Sciences reported sales of $9.14 million during the same quarter last year, which indicates a positive year-over-year growth rate of 44.9%. The firm is scheduled to issue its next earnings results on Wednesday, March 27th.
According to Zacks, analysts expect that Alimera Sciences will report full year sales of $45.10 million for the current fiscal year, with estimates ranging from $45.06 million to $45.14 million. For the next financial year, analysts forecast that the business will post sales of $55.18 million, with estimates ranging from $52.70 million to $57.65 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that cover Alimera Sciences.
Several brokerages have recently issued reports on ALIM. ValuEngine upgraded shares of Alimera Sciences from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. HC Wainwright set a $3.00 price target on shares of Alimera Sciences and gave the stock a “buy” rating in a research note on Tuesday, November 27th. Zacks Investment Research downgraded shares of Alimera Sciences from a “hold” rating to a “sell” rating in a research note on Thursday, February 21st. Finally, TheStreet downgraded shares of Alimera Sciences from a “c-” rating to a “d” rating in a research note on Monday, December 3rd. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. Alimera Sciences presently has a consensus rating of “Hold” and an average target price of $2.44.
Several hedge funds have recently made changes to their positions in ALIM. B. Riley Wealth Management Inc. grew its holdings in Alimera Sciences by 23.5% during the 4th quarter. B. Riley Wealth Management Inc. now owns 101,906 shares of the biopharmaceutical company’s stock worth $73,000 after acquiring an additional 19,407 shares in the last quarter. Knott David M grew its stake in Alimera Sciences by 20.1% in the fourth quarter. Knott David M now owns 387,901 shares of the biopharmaceutical company’s stock valued at $279,000 after purchasing an additional 65,001 shares in the last quarter. Royce & Associates LP grew its stake in Alimera Sciences by 60.2% in the fourth quarter. Royce & Associates LP now owns 319,186 shares of the biopharmaceutical company’s stock valued at $229,000 after purchasing an additional 120,000 shares in the last quarter. Renaissance Technologies LLC grew its stake in Alimera Sciences by 27.7% in the third quarter. Renaissance Technologies LLC now owns 732,790 shares of the biopharmaceutical company’s stock valued at $718,000 after purchasing an additional 158,790 shares in the last quarter. Finally, B. Riley Financial Inc. bought a new position in Alimera Sciences in the third quarter valued at approximately $447,000. Hedge funds and other institutional investors own 50.32% of the company’s stock.
About Alimera Sciences
Alimera Sciences, Inc, a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness.
Recommended Story: What is the price-to-earnings growth (PEG) ratio?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.